Rapid Drug Discovery Service Suite
Canadian-based company with a single asset successfully progressing through the clinic and in need of building a preclinical pipeline of related and proprietary NCE’s and programs to treat pain and inflammation.
Dalriada’s Turn-Key™ Approach
Assessed IP landscape
- Identified competing IP.
- Identified available IP white space to lengthen the duration of patent and market protection.
Designed & implemented a drug discovery effort
- Designed molecules with similar mechanism of action to the clinical asset.
- Established libraries of >100 analogs/homologs in multiple series.
- Ran orthogonal, biochemical & biological screens for IND-enabling studies.
- Designed and managed all in vivo studies for lead NCEs.
Resulting in a successful outcome…
- Delivered lead NCE’s with comparable potency and efficacy to the clinical asset.
- 2-year program ongoing and progressing towards DC nomination.
When we began working with Dalriada, we sought to tap their deep medicinal chemistry expertise; since then, they’ve consistently exceeded our expectations, particularly impressing us with their responsive, resourceful and positive approach. Always with a thoughtful eye to IP protection and commercial viability, they’ve worked efficiently to identify several potential candidates.